Positron emission tomography (PET), particularly using radiotracers like PSMA (prostate-specific membrane antigen), has shown promise in both accurately delineating tumor extent and guiding treatment decisions, including the use of theranostic agents. Here, FOLH1 is linked to neoplasm.